Spread across the body’s central nervous system, GI tract, and other organs, there is a family of somatostatin receptors (SSTRs). These receptors are proteins that live on the surface of cells and they bind to the somatostatin hormone. There are five SSTR receptors (SSTR1, 2, etc.).
SSTRs play a critical role in keeping the body healthy, as they help regulate the amount of hormones being released, influence several bodily functions, and manage cell growth, division, and survival across multiple organs.
In many NET cancers, SSTR2 is increased, which is called “overexpressed.” In this case, a patient may become a candidate for targeted therapy. SSTR5 may also be expressed.
Imaging tests like PET scans and CT/MRI can be performed to assess SSTR during the staging or monitoring of NET cancer. Additionally, a biopsy on solid tumor tissue may be performed to identify specific SSTRs on a tumor. Test results like “SSTR-positive” or “SSTR-negative” will determine eligibility for targeted treatments.
If your NET cancer overexpresses SSTR, you may receive the following treatments:
Your treatment plan will be unique and dependent on several factors. Ask your doctor how your biomarker test results are informing your treatment plan and if you qualify for any clinical trials.
